Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease

Adalimumab is a monoclonal antibody used for inflammatory bowel disease. Due to its considerably variable pharmacokinetics, the loss of response and the development of anti-antibodies, it is highly recommended to use a model-informed precision dosing approach. The aim of this study is to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquez-Megias, Silvia, Ramon-Lopez, Amelia, Más-Serrano, Patricio, Diaz-Gonzalez, Marcos, Candela-Boix, Maria Remedios, Nalda-Molina, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398570/
https://www.ncbi.nlm.nih.gov/pubmed/34452204
http://dx.doi.org/10.3390/pharmaceutics13081244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398570/
https://www.ncbi.nlm.nih.gov/pubmed/34452204
http://dx.doi.org/10.3390/pharmaceutics13081244

Ejemplares similares